About James La Rossa

This author has not yet filled in any details.
So far James La Rossa has created 176 blog entries.

Facebook to Expand Artificial Intelligence to Help Prevent Suicide

By |2017-11-30T11:29:58-08:00November 30th, 2017|Brief Bulletins from the Field, We Know Psychiatry|

SAN FRANCISCO (Reuters) - Facebook Inc will expand its pattern recognition software to other countries after successful tests in the U.S. to detect users with suicidal intent, the world's largest social media network said on Monday. Facebook began testing the software in the United States in March, when the company [...]

FDA Approves Vraylar for Schizophrenia in Adults

By |2017-11-30T11:30:29-08:00November 30th, 2017|Brief Bulletins from the Field, We Know Psychiatry|

Allergan plc has announced that the US Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Vraylar (cariprazine) for the maintenance treatment of adults with schizophrenia. Vraylar is also approved in the US in adults for the acute treatment of schizophrenia and acute treatment of [...]

NIMH: Ketamine-Like Hallucinogens May Offer New Hope for Treatment-Resistant Depression

By |2021-11-11T17:04:19-08:00November 16th, 2017|Brief Bulletins from the Field, We Know Psychiatry|

In 2006, psychiatrist Carlos A. Zarate Jr, MD, and colleagues at the National Institute of Mental Health (NIMH) published a seminal finding in Archives of General Psychiatry (now JAMA Psychiatry): A single intravenous dose of ketamine—an anesthetic agent with hallucinogenic properties—produced robust antidepressant effects in patients with treatment-resistant depression (TRD) [...]

Digital Tattletales: New Technology Alerts Drug Non-Compliance

By |2021-11-11T17:04:28-08:00November 15th, 2017|Brief Bulletins from the Field, We Know Psychiatry|

The antipsychotic agent, Abilify (aripiprazole, Otsuka), is the first Food and Drug Administration approved digital pill — a medication embedded with a sensor that can tell doctors whether, and when, patients take their medicine. The wearable sensor patch is made by Proteus Digital Health. The approval marks a significant advance in [...]

Study Finds Competing Opioid Treatments Same, with One Caveat

By |2021-11-11T17:04:39-08:00November 15th, 2017|Brief Bulletins from the Field, We Know Psychiatry|

A long-awaited study has found that two of the main medications for treating opioid addiction are similarly effective. The study, funded by the federal government, compared Vivitrol, which comes in a monthly shot and blocks the effects of opioids, and Suboxone, which is taken daily in strips that dissolve on the [...]

Can an App that Tracks Medication Doses and Mood Swings Help Improve Depression Treatment?

By |2021-11-11T17:04:51-08:00November 13th, 2017|Brief Bulletins from the Field, We Know Psychiatry|

PHARMA NEWS Takeda and Lundbeck are planning a  U.S. test for a depression app that will track mood, in the hopes it will improve depression treatment. The two pharma companies have teamed up with Advocate Health Care on a study that uses an app with a “conversational text interface” to track and [...]

Brain Inflammation Tied to Depression and Suicidal Thoughts

By |2021-11-11T17:05:01-08:00November 13th, 2017|Brief Bulletins from the Field, We Know Psychiatry|

On individuals with major depressive disorder (MDD), particularly those who experience suicidal thinking, levels of translocator protein (TSPO), a marker of microglial inflammation, are increased, new research shows. Investigators from the University of Manchester, United Kingdom, found significantly higher levels of TSPO in patients with MDD than in healthy control [...]

Effectiveness of Online Collaborative Care for Treating Mood and Anxiety Disorders in Primary Care: A Randomized Clinical Trial

By |2021-11-11T17:05:12-08:00November 13th, 2017|Brief Bulletins from the Field, We Know Psychiatry|

By Bruce L. Rollman, Bea Herbeck Belnap, Biol Hum, Kaleab Z. Abebe Key Points Questions  Is combining an internet support group (ISG) with a care manager–guided computerized cognitive behavioral therapy (CCBT) program better at treating depression and anxiety than CCBT alone and better than primary care physicians’ usual care for these conditions? Findings  Among [...]

JAMA Issues Advance Directives for Dementia

By |2017-11-06T17:57:54-08:00November 6th, 2017|Brief Bulletins from the Field, We Know Psychiatry|

Viewpoint November 6, 2017 Advance Directives for Dementia: Meeting a Unique Challenge By Barak Gaster, Eric B. Larson,  and J. Randall Curtis   In the coming years, an increasing number of people will experience dementia. Worldwide, the number of people living with dementia is projected to increase from 47 million in 2015 to 132 million by [...]

Go to Top